301 related articles for article (PubMed ID: 32042194)
1. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.
Painter CA; Jain E; Tomson BN; Dunphy M; Stoddard RE; Thomas BS; Damon AL; Shah S; Kim D; Gómez Tejeda Zañudo J; Hornick JL; Chen YL; Merriam P; Raut CP; Demetri GD; Van Tine BA; Lander ES; Golub TR; Wagle N
Nat Med; 2020 Feb; 26(2):181-187. PubMed ID: 32042194
[TBL] [Abstract][Full Text] [Related]
2. Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Megquier K; Turner-Maier J; Swofford R; Kim JH; Sarver AL; Wang C; Sakthikumar S; Johnson J; Koltookian M; Lewellen M; Scott MC; Schulte AJ; Borst L; Tonomura N; Alfoldi J; Painter C; Thomas R; Karlsson EK; Breen M; Modiano JF; Elvers I; Lindblad-Toh K
Mol Cancer Res; 2019 Dec; 17(12):2410-2421. PubMed ID: 31570656
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape of primary breast angiosarcoma with repeated resection and recurrence over a 15-year period: A case report.
Teruyama F; Kuno A; Murata Y; Nakagawa T; Shiba-Ishii A; Yuguchi S; Noguchi M
Pathol Int; 2022 Sep; 72(9):457-463. PubMed ID: 35801418
[TBL] [Abstract][Full Text] [Related]
4. Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Beca F; Krings G; Chen YY; Hosfield EM; Vohra P; Sibley RK; Troxell ML; West RB; Allison KH; Bean GR
Mod Pathol; 2020 Aug; 33(8):1518-1526. PubMed ID: 32123305
[TBL] [Abstract][Full Text] [Related]
5. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.
Rosenbaum E; Antonescu CR; Smith S; Bradic M; Kashani D; Richards AL; Donoghue M; Kelly CM; Nacev B; Chan JE; Chi P; Dickson MA; Keohan ML; Gounder MM; Movva S; Avutu V; Thornton K; Zehir A; Bowman AS; Singer S; Tap W; D'Angelo S
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365586
[TBL] [Abstract][Full Text] [Related]
6. Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies.
Zhrebker L; Cherni I; Gross LM; Hinshelwood MM; Reese M; Aldrich J; Guileyardo JM; Roberts WC; Craig D; Von Hoff DD; Mennel RG; Carpten JD
BMC Cancer; 2017 Jan; 17(1):17. PubMed ID: 28056866
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
8. Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Wan H; Zhang D; Hu W; Xie Z; Du Q; Xia Q; Wen T; Jia H
Medicine (Baltimore); 2021 Jul; 100(30):e26779. PubMed ID: 34397726
[TBL] [Abstract][Full Text] [Related]
9. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.
Boichard A; Wagner MJ; Kurzrock R
Genome Med; 2020 Jul; 12(1):61. PubMed ID: 32646514
[TBL] [Abstract][Full Text] [Related]
10. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.
Huang SC; Zhang L; Sung YS; Chen CL; Kao YC; Agaram NP; Singer S; Tap WD; D'Angelo S; Antonescu CR
Am J Surg Pathol; 2016 May; 40(5):645-55. PubMed ID: 26735859
[TBL] [Abstract][Full Text] [Related]
11. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.
Momen S; Fassihi H; Davies HR; Nikolaou C; Degasperi A; Stefanato CM; Dias JML; Dasgupta D; Craythorne E; Sarkany R; Papa S; Nik-Zainal S
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645345
[TBL] [Abstract][Full Text] [Related]
12. Identification of genetic alterations in extramammary Paget disease using whole exome analysis.
Kiniwa Y; Yasuda J; Saito S; Saito R; Motoike IN; Danjoh I; Kinoshita K; Fuse N; Yamamoto M; Okuyama R
J Dermatol Sci; 2019 Apr; 94(1):229-235. PubMed ID: 31023612
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
[TBL] [Abstract][Full Text] [Related]
14. Actionable mutations in canine hemangiosarcoma.
Wang G; Wu M; Maloneyhuss MA; Wojcik J; Durham AC; Mason NJ; Roth DB
PLoS One; 2017; 12(11):e0188667. PubMed ID: 29190660
[TBL] [Abstract][Full Text] [Related]
15. Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma.
Estabrooks T; Gurinovich A; Pietruska J; Lewis B; Harvey G; Post G; Lambert L; Miller A; Rodrigues L; White ME; Lopes C; London CA; Megquier K
Vet Comp Oncol; 2023 Dec; 21(4):623-633. PubMed ID: 37734854
[TBL] [Abstract][Full Text] [Related]
16. POT1 and Damage Response Malfunction Trigger Acquisition of Somatic Activating Mutations in the VEGF Pathway in Cardiac Angiosarcomas.
Calvete O; Garcia-Pavia P; Domínguez F; Mosteiro L; Pérez-Cabornero L; Cantalapiedra D; Zorio E; Ramón Y Cajal T; Crespo-Leiro MG; Teulé Á; Lázaro C; Morente MM; Urioste M; Benitez J
J Am Heart Assoc; 2019 Sep; 8(18):e012875. PubMed ID: 31510873
[TBL] [Abstract][Full Text] [Related]
17. Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure.
Huang SC; Chang IY; Chang CJ; Liu H; Chen KH; Liu TT; Hsieh TY; Chuang HC; Chen CC; Lin IC; Ng KF; Huang HY; Chen TC
J Pathol; 2023 Jun; 260(2):165-176. PubMed ID: 36815532
[TBL] [Abstract][Full Text] [Related]
18. Initiative Suggests Angiosarcoma Therapies.
Cancer Discov; 2020 Apr; 10(4):481-482. PubMed ID: 32122879
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.
Morris V; Rao X; Pickering C; Foo WC; Rashid A; Eterovic K; Kim T; Chen K; Wang J; Shaw K; Eng C
Mol Cancer Res; 2017 Nov; 15(11):1542-1550. PubMed ID: 28784613
[TBL] [Abstract][Full Text] [Related]
20. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]